CTRI/2018/04/013399
Not yet recruiting
Phase 3
A randomized study to compare gefitinib with bevacizumab vs gefitinib in EGFR mutation positive non-small cell lung cancer in the palliative setting.
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Lung Cancer Patients
- Sponsor
- Tata Memorial Hospital
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patient aged \>\= 18 years
- •2\.Histologically or cytologically confirmed NSCLC with EGFR mutation positive for exon 19, 21 or 18
- •3\.Disease is not amenable to curative intent therapy; palliative intent therapy is planned.
- •4\.No prior palliative chemotherapy, or palliative biological (including targeted therapies such as EGFR and vascular epidermal growth factor inhibitors) or immunological therapy.Previous adjuvant chemotherapy is permitted if treatment was completed at least 6 months before day 1\. Palliative radiotherapy to a metastatic site is permitted.
- •5\.Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) with at least one measurable lesion.
- •6\.ECOG performance status (PS) of 0 to 2
- •7\.Adequate organ function, including the following:
- •i)Adequate bone marrow reserve: absolute neutrophil counts (ANC) \>\= 1\.5X109/L, Platelets \>\=100X109/L
- •ii)Hepatic: bilirubin \<\= 1\.5 times the upper limit of normal(x ULN), alanine aminotransferase (ALT) \& aspartate aminotransferase (AST) \<\= 3\.0 times the ULN if no demonstrable liver metastases (AST,ALT \<\= 5 XULN is acceptable if liver is involved by tumour).
- •iii)Renal: Serum creatinine \<\= 1\.5 x ULN or creatinine clearance \>\= 50 ml/min
Exclusion Criteria
- •1\.Known severe hypersensitivity to gefitinib or any of the excipients of this product
- •2\.Known severe hypersensitivity to bevacizumabor any of the excipients of this product.
- •3\.History or presence of any other malignancy within the last 3 years, with the exception of basal cell carcinoma of the skin or cervical cancer in situ
- •4\.Past medical history of interstitial lung disease, drug induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease.
- •5\.Pre\-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline.
- •6\.Any unresolved chronic toxicity greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 2 from previous anticancer therapy.
- •7\.As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease).
- •8\.Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study.
- •9\.Pregnancy or breast feeding
- •10\.Life expectancy of \<\= 12 weeks
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
A study to compare Gefitinib tablet with Gefitinib and Chemotherapy inEGFR Mutation Positive Lung cancer patientsHealth Condition 1: C399- Malignant neoplasm of lower respiratory tract, part unspecifiedCTRI/2022/08/044570Tata Memorial Centre
Not yet recruiting
Not Applicable
A study to compare survival with Oral TKI against Oral TKI and intravenous chemotherapy in advanced lung cancer patientsHealth Condition 1: null- Patients who have EGFR mutation positive Non small Cell lung cancerCTRI/2016/08/007149Tata Memorial Centre350
Recruiting
Phase 2
Randomised phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with EGFR mutant non-squamous non small cell lung cancenon small cell lung cancerJPRN-UMIN000013586BAGEL study group90
Completed
Phase 3
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)advanced non-squamous non-small cell lung cancer harboring EGFR mutaitonJPRN-UMIN000020242Japan Clinical Oncology Group (JCOG)500
Completed
Not Applicable
Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)on-small cell lung cancerJPRN-UMIN000006340orth-East Japan Study Group345